anti-IL-17/IL-23 bispecific antibody (BMS)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-IL-17/IL-23 bispecific antibody (BMS)
Drug Alias NameIL-17/IL-23 biAb (Bristol-Myers Squibb)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-17 agonistsInterleukin-23 stimulants
TargetsInterleukin-23Interleukin-17
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A